Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

11.10 +0.28 (+2.54%)
Streaming Delayed Price Updated: 2:06 PM EDT, Aug 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares

< Previous 1 2 Next >
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Telix H1 2025 Results: Investor Webcast Notification
From Telix Pharmaceuticals Limited
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX
From Pomerantz LLP
Via GlobeNewswire
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
From Glancy Prongay & Murray LLP
Via Business Wire
Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
From Law Offices of Howard G. Smith
Via Business Wire
Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
From The Law Offices of Frank R. Cruz
Via Business Wire
Telix Reports $204M Revenue, Up 63% YOY
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Gozellix Receives Permanent HCPCS Code
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Illuccix Approved in U.S. for Patient Selection for Pre-Taxane RLT
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Precision Medicine Announces AlFluor Radiochemistry Platform
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Launches New Prostate Cancer Imaging Agent, Gozellix, in U.S.
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Investor Day in New York City on June 11, 2025: Presenting KOLs
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix to Host Investor Day in New York City on June 11, 2025
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix's Illuccix PSMA-PET Imaging Agent Approved in France
New approval provides French hospitals and clinics with access to a proven PSMA-PET imaging agent 
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Reports US$186M Q1 Revenue, Up 62% YOY
From Telix Pharmaceuticals Limited
Via GlobeNewswire
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Announces Cardinal Health for Gozellix Commercial Distribution
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Appoints Paul Schaffer as Chief Technology Officer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Anne Whitaker Appointed as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Announces First Patient Dosed in First-in-Human ZOLAR Trial of TLX300-CDx in Advanced Soft Tissue Sarcoma
From Telix Pharmaceuticals Limited
Via GlobeNewswire
ARTMS Drug Master File for Gallium Production Technology Referenced with Telix’s Gozellix®
From Telix ARTMS, Inc.
Via GlobeNewswire
FDA Approves New Prostate Cancer Imaging Agent Gozellix®
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America
From Telix Pharmaceuticals Limited
Via GlobeNewswire
Telix Adds Lead-212 Isotope Production Capability
From Telix Pharmaceuticals Limited
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.